Published in Annu Rev Public Health on December 14, 2012
How can mathematical models advance tuberculosis control in high HIV prevalence settings? Int J Tuberc Lung Dis (2014) 1.49
Diabetes and immunity to tuberculosis. Eur J Immunol (2014) 1.45
Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries. Proc Natl Acad Sci U S A (2014) 1.21
Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas. Antimicrob Agents Chemother (2014) 1.16
Tuberculosis Infection in the United States: Prevalence Estimates from the National Health and Nutrition Examination Survey, 2011-2012. PLoS One (2015) 1.15
The ongoing challenge of latent tuberculosis. Philos Trans R Soc Lond B Biol Sci (2014) 1.12
Global epidemiology of tuberculosis. Cold Spring Harb Perspect Med (2014) 1.11
Tuberculosis: From an incurable scourge to a curable disease - journey over a millennium. Indian J Med Res (2013) 1.01
How much is tuberculosis screening worth? Estimating the value of active case finding for tuberculosis in South Africa, China, and India. BMC Med (2014) 1.01
Molecular profiling of Mycobacterium tuberculosis identifies tuberculosinyl nucleoside products of the virulence-associated enzyme Rv3378c. Proc Natl Acad Sci U S A (2014) 0.99
The role of B cells and humoral immunity in Mycobacterium tuberculosis infection. Semin Immunol (2014) 0.98
Immune requirements for protective Th17 recall responses to Mycobacterium tuberculosis challenge. Mucosal Immunol (2015) 0.97
Comparison of trends in tuberculosis incidence among adults living with HIV and adults without HIV--Kenya, 1998-2012. PLoS One (2014) 0.97
After 2015: infectious diseases in a new era of health and development. Philos Trans R Soc Lond B Biol Sci (2014) 0.94
Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection. Lancet (2015) 0.94
Tuberculosis control in China: use of modelling to develop targets and policies. Bull World Health Organ (2015) 0.94
Interleukin 27R regulates CD4+ T cell phenotype and impacts protective immunity during Mycobacterium tuberculosis infection. J Exp Med (2015) 0.93
Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. J Thorac Dis (2015) 0.91
Antibodies and tuberculosis. Tuberculosis (Edinb) (2016) 0.90
Control of Mycobacterial Infections in Mice Expressing Human Tumor Necrosis Factor (TNF) but Not Mouse TNF. Infect Immun (2015) 0.89
Perspective: Weigh all TB risks. Nature (2013) 0.88
Transforming the fight against tuberculosis: targeting catalysts of transmission. Clin Infect Dis (2014) 0.87
Helminth-induced arginase-1 exacerbates lung inflammation and disease severity in tuberculosis. J Clin Invest (2015) 0.86
Latent Tuberculosis: Models, Computational Efforts and the Pathogen's Regulatory Mechanisms during Dormancy. Front Bioeng Biotechnol (2013) 0.85
Qualification of a whole blood intracellular cytokine staining assay to measure mycobacteria-specific CD4 and CD8 T cell immunity by flow cytometry. J Immunol Methods (2014) 0.84
Design of Potential Bisubstrate Inhibitors against Mycobacterium tuberculosis (Mtb) 1-Deoxy-D-Xylulose 5-Phosphate Reductoisomerase (Dxr)-Evidence of a Novel Binding Mode. Medchemcomm (2013) 0.83
Barriers to adherence with tuberculosis contact investigation in six provinces of Vietnam: a nested case-control study. BMC Infect Dis (2015) 0.81
Characterization of W-Beijing isolates of Mycobacterium tuberculosis from the Western Cape. Vaccine (2013) 0.81
Bridging the gap between evidence and policy for infectious diseases: How models can aid public health decision-making. Int J Infect Dis (2015) 0.81
Dietary Vitamin D3 Suppresses Pulmonary Immunopathology Associated with Late-Stage Tuberculosis in C3HeB/FeJ Mice. J Immunol (2016) 0.80
Vaccines against tuberculosis: moving forward with new concepts. Expert Rev Vaccines (2013) 0.80
Chemokines in tuberculosis: the good, the bad and the ugly. Semin Immunol (2014) 0.80
Role of casual contacts in the recent transmission of tuberculosis in settings with high disease burden. Clin Microbiol Infect (2014) 0.80
Neither primary nor memory immunity to Mycobacterium tuberculosis infection is compromised in mice with chronic enteric helminth infection. Infect Immun (2015) 0.79
Modeling the potential impact of host population survival on the evolution of M. tuberculosis latency. PLoS One (2014) 0.79
(Not) measuring in the dark. Int J Tuberc Lung Dis (2015) 0.78
Modelling challenges in context: lessons from malaria, HIV, and tuberculosis. Epidemics (2015) 0.78
Systematic review of mathematical models exploring the epidemiological impact of future TB vaccines. Hum Vaccin Immunother (2016) 0.78
Falling Short of the Rights to Health and Scientific Progress: Inadequate TB Drug Research and Access. Health Hum Rights (2016) 0.77
Tuberculosis prevention in South Africa. PLoS One (2015) 0.77
Cough Aerosols of Mycobacterium tuberculosis in the Prediction of Incident Tuberculosis Disease in Household Contacts. Clin Infect Dis (2016) 0.77
Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS (2016) 0.77
Health Care Visits as a Risk Factor for Tuberculosis in Taiwan: A Population-Based Case-Control Study. Am J Public Health (2016) 0.77
Phylogenetic analysis of vitamin B12-related metabolism in Mycobacterium tuberculosis. Front Mol Biosci (2015) 0.76
Effect of isoniazid on antigen-specific interferon-γ secretion in latent tuberculosis. Eur Respir J (2014) 0.76
The effect of chain length and unsaturation on Mtb Dxr inhibition and antitubercular killing activity of FR900098 analogs. Bioorg Med Chem Lett (2013) 0.76
Prevalence of latent tuberculosis infection and predictive factors in an urban informal settlement in Johannesburg, South Africa: a cross-sectional study. BMC Infect Dis (2016) 0.75
Predicting IFN-γ responses after BCG vaccination in humans from macaques: A proof-of-concept study of Immunostimulation/Immunodynamic modelling methods. Clin Vaccine Immunol (2017) 0.75
A novel indication for a method in the treatment of lumbar tuberculosis through minimally invasive extreme lateral interbody fusion (XLIF) in combination with percutaneous pedicle screws fixation in an elderly patient: A case report. Medicine (Baltimore) (2016) 0.75
Adenovirally-Induced Polyfunctional T Cells Do Not Necessarily Recognize the Infected Target: Lessons from a Phase I Trial of the AERAS-402 Vaccine. Sci Rep (2016) 0.75
Rationalized design of a mucosal vaccine protects against Mycobacterium tuberculosis challenge in mice. J Leukoc Biol (2017) 0.75
Isoniazid preventive treatment among child contacts of adults with smear-positive tuberculosis in The Gambia. Public Health Action (2016) 0.75
High-throughput identification and dendritic cell-based functional validation of MHC class I-restricted Mycobacterium tuberculosis epitopes. Sci Rep (2014) 0.75
Cytokines and Chemokines in Mycobacterium tuberculosis Infection. Microbiol Spectr (2016) 0.75
Structure-Activity Relationships of the MEPicides: N-Acyl and O-Linked Analogs of FR900098 as Inhibitors of Dxr from Mycobacterium tuberculosis and Yersinia pestis. ACS Infect Dis (2016) 0.75
Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection. Hum Vaccin Immunother (2016) 0.75
Effect of bacillus Calmette-Guérin vaccination on CD4+Foxp3+ T cells during acquired immune response to Mycobacterium tuberculosis infection. J Leukoc Biol (2015) 0.75
A Collaborative Approach for "ReSeq-ing" Mycobacterium tuberculosis Drug Resistance: Convergence for Drug and Diagnostic Developers. EBioMedicine (2015) 0.75
Results of tuberculosis contact investigation in congregate settings in Korea, 2013. Osong Public Health Res Perspect (2014) 0.75
A review of clinical models for the evaluation of human TB vaccines. Hum Vaccin Immunother (2016) 0.75
Improving Control of Tuberculosis in Low-Burden Countries: Insights from Mathematical Modeling. Front Microbiol (2016) 0.75
Experimental study of tuberculosis: From animal models to complex cell systems and organoids. PLoS Pathog (2017) 0.75
Burden of non-adherence to latent tuberculosis infection drug therapy and the potential cost-effectiveness of adherence interventions in Canada: a simulation study. BMJ Open (2017) 0.75
Novel role for IL-22 in protection during chronic Mycobacterium tuberculosis HN878 infection. Mucosal Immunol (2017) 0.75
Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet (2009) 7.22
Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet (2010) 7.07
Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet (2002) 6.47
Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med (2009) 5.93
Tuberculosis. N Engl J Med (2013) 4.75
Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet (2006) 4.73
Latent Mycobacterium tuberculosis infection. N Engl J Med (2015) 4.62
Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ (2011) 4.19
Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet (2002) 3.67
Interventions to reduce tuberculosis mortality and transmission in low- and middle-income countries. Bull World Health Organ (2002) 3.03
Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLoS Med (2006) 2.99
Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet (2012) 2.83
Global epidemiology of tuberculosis: prospects for control. Semin Respir Crit Care Med (2008) 2.57
Cost effectiveness analysis of strategies for tuberculosis control in developing countries. BMJ (2005) 2.50
MDR tuberculosis--critical steps for prevention and control. N Engl J Med (2010) 2.49
Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. Eur Respir J (2012) 2.47
Tuberculosis control in the era of HIV. Nat Rev Immunol (2005) 2.40
A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics (2012) 2.36
The global fight against HIV/AIDS, tuberculosis, and malaria: current status and future perspectives. Am J Clin Pathol (2009) 2.34
Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis (2013) 2.16
Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence. BMC Public Health (2005) 2.09
Global tuberculosis control: lessons learnt and future prospects. Nat Rev Microbiol (2012) 2.05
Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data. Lancet Infect Dis (2013) 1.96
The WHO policy package to combat antimicrobial resistance. Bull World Health Organ (2011) 1.93
XDR-TB: entering the post-antibiotic era? Int J Tuberc Lung Dis (2006) 1.86
Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS (2010) 1.77
Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis (2012) 1.72
Variations in the sequence and expression of the Plasmodium falciparum chloroquine resistance transporter (Pfcrt) and their relationship to chloroquine resistance in vitro. Mol Biochem Parasitol (2004) 1.71
Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis. Eur Respir J (2012) 1.70
Global epidemiology of tuberculosis. Semin Respir Crit Care Med (2013) 1.66
Lives saved by tuberculosis control and prospects for achieving the 2015 global target for reducing tuberculosis mortality. Bull World Health Organ (2011) 1.64
Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts. Lancet Infect Dis (2013) 1.62
HIV, STIs, and sexual behaviors among men who have sex with men in Phnom Penh, Cambodia. AIDS Educ Prev (2004) 1.59
Global epidemiology of tuberculosis. Clin Chest Med (2005) 1.59
Assessing tuberculosis case fatality ratio: a meta-analysis. PLoS One (2011) 1.49
Antiretroviral therapy for tuberculosis control in nine African countries. Proc Natl Acad Sci U S A (2010) 1.48
New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis (2012) 1.46
The effect of tuberculosis on mortality in HIV positive people: a meta-analysis. PLoS One (2010) 1.46
Resources required for global tuberculosis control. Science (2002) 1.43
How human immunodeficiency virus voluntary testing can contribute to tuberculosis control. Bull World Health Organ (2003) 1.43
Tuberculosis elimination: theory and practice in Europe. Eur Respir J (2014) 1.42
Modernizing surveillance of antituberculosis drug resistance: from special surveys to routine testing. Clin Infect Dis (2011) 1.41
Global burden and epidemiology of tuberculosis. Clin Chest Med (2009) 1.35
Chronic diarrhea, hemorrhagic colitis, and hemolytic-uremic syndrome associated with HEp-2 adherent Escherichia coli in adults infected with human immunodeficiency virus in Bangui, Central African Republic. J Clin Microbiol (2002) 1.29
Tuberculosis control is crucial to achieve the MDGs. Lancet (2010) 1.22
A community-based tuberculosis program in Cambodia. JAMA (2004) 1.21
Planning to improve global health: the next decade of tuberculosis control. Bull World Health Organ (2007) 1.19
A systematic review of the effectiveness of hospital- and ambulatory-based management of multidrug-resistant tuberculosis. Am J Trop Med Hyg (2013) 1.16
Secondary dengue virus type 4 infections in Vietnam. Southeast Asian J Trop Med Public Health (2005) 1.16
Tuberculosis: still a social disease. Int J Tuberc Lung Dis (2011) 1.11
Prevention, diagnosis, and treatment of tuberculosis in children and mothers: evidence for action for maternal, neonatal, and child health services. J Infect Dis (2012) 1.09
Stopping tuberculosis in the 21st century: goals and strategies. Respirology (2010) 1.08
The health workforce crisis in TB control: a report from high-burden countries. Hum Resour Health (2005) 1.04
Multidrug-resistant tuberculosis in children: evidence from global surveillance. Eur Respir J (2012) 1.03
Active case-finding for TB in the community: time to act. Lancet (2010) 1.03
Implementing the global plan to stop TB, 2011-2015--optimizing allocations and the Global Fund's contribution: a scenario projections study. PLoS One (2012) 1.01
Tuberculosis and HIV in people who inject drugs: evidence for action for tuberculosis, HIV, prison and harm reduction services. Curr Opin HIV AIDS (2012) 1.00
Managing tuberculosis in people who use and inject illicit drugs. Bull World Health Organ (2013) 1.00
Reaching the global tuberculosis control targets in the Western Pacific Region. Bull World Health Organ (2007) 1.00
The research agenda for improving health policy, systems performance, and service delivery for tuberculosis control: a WHO perspective. Bull World Health Organ (2002) 0.98
Using the TIME model in Spectrum to estimate tuberculosis-HIV incidence and mortality. AIDS (2014) 0.97
Tuberculosis mortality in HIV-infected individuals: a cross-national systematic assessment. Clin Epidemiol (2011) 0.93
Global Tuberculosis Control: Toward the 2015 Targets and Beyond. Ann Intern Med (2015) 0.92
Treatment of tuberculosis. BMJ (2003) 0.92
Tuberculosis and air travel: WHO guidance in the era of drug-resistant TB. Travel Med Infect Dis (2007) 0.92
Limitations on human rights: are they justifiable to reduce the burden of TB in the era of MDR- and XDR-TB? Health Hum Rights (2008) 0.91
Feasibility of antenatal and late HIV testing in pregnant women in Phnom Penh Cambodia: the PERIKAM/ANRS1205 study. AIDS (2002) 0.91
Transforming the global tuberculosis response through effective engagement of civil society organizations: the role of the World Health Organization. Bull World Health Organ (2011) 0.90
Perspective: Weigh all TB risks. Nature (2013) 0.88
Monitoring global health: WHO has mandate and expertise. BMJ (2005) 0.86
WHO policies for tuberculosis control. Lancet (2004) 0.84
Toward tuberculosis elimination in low-incidence countries: reflections from a global consultation. Ann Intern Med (2014) 0.83
WHO guidance on electronic systems to manage data for tuberculosis care and control. J Am Med Inform Assoc (2012) 0.82
Reply to 'Addressing smoking cessation in tuberculosis control'. Bull World Health Organ (2007) 0.82
Latent Mycobacterium tuberculosis Infection. N Engl J Med (2015) 0.80
Erring on the side of action: time for HIV programmes to implement isoniazid preventive therapy. Int J Tuberc Lung Dis (2009) 0.80
Characterization of mutations in HIV type 1 isolates from 144 Cambodian recently infected patients and pregnant women naive to antiretroviral drugs. AIDS Res Hum Retroviruses (2005) 0.79
New methods for estimating the tuberculosis case detection rate in high-HIV prevalence countries: the example of Kenya. Bull World Health Organ (2009) 0.79
Linezolid for extensively drug-resistant tuberculosis. N Engl J Med (2013) 0.78
Challenges and controversies in defining totally drug-resistant tuberculosis. Emerg Infect Dis (2012) 0.78
Household tuberculosis interventions--how confident are we? Lancet (2013) 0.78
Quality tuberculosis care. All should adopt the new international standards for tuberculosis care. Ann Am Thorac Soc (2014) 0.78
WHO's relationship with the Stop TB Partnership. Lancet (2012) 0.78
Moving the goalposts for tuberculosis targets in Africa. Lancet (2013) 0.75